Corneal graft rejection

International Ophthalmology Clinics

Volumn 49, Issue 1, 2009, Pages 31-41

  Lam, Helene ^a   Dana, M Reza ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; PREDNISONE; PREDNISONE ACETATE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

CORNEA TRANSPLANTATION; GRAFT REJECTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CORNEAL TRANSPLANTATION; GRAFT REJECTION; HUMANS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 59449107461     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e3181924e23     Document Type: Review

References (62)

1. Aiken-O'Neill P, Mannis M. Summary of corneal transplant activity Eye Bank Association of America. Cornea. 2002;21:1-3.
2. Williams KA, Muehlberg SM, Wing SJ, eds. The Australian corneal graft registry. Aust NZ J Ophthalmol. 1993;21(2 suppl):l-48.
3. Price FW, Jr, Whitson WE, Collins KS. Five-year corneal graft survival. A large, single-center patient cohort. Arch Ophthalmol. 1993;111:799-805.
4. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599-604.
5. Maumenee A. Clinical aspects of the corneal homograft reaction. Invest Ophthalmol. 1962;1:244-252.
6. Medawar P. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
7. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci. 1984;25:519-524.
8. Nussenblat RB. Elements of the immune system and concepts of intraocular inflammatory disease pathogenesis. In: Nussenblatt RB, Whitcup SM, eds. Uveitis Fundamentals and Clinical Practice. 3rd ed. Philadelphia: Mosby; 2004:3-18.
9. Streilein J. Immunobiology and immunopathology of corneal transplantation. Chem Immunol. 1999;73:186-206.
10. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation. 2007;84:806-813.
11. Wilson SE, Li Q, Weng J, et al. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol. 1996;37:158.
12. Shen L, Jin Y, Freeman GJ, et al. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007;179:3672-3679.
13. Niederkorn J, Streilein J. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J Immunol. 1983;131:2670-2674.
14. Streilein J. Unraveling immune privilege. Science. 1995;270:1158.
15. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology. Cornea. 2000;19:625-643.
16. Niederkorn J. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007; 32:1005-1016.
17. Niederkorn J. Mechanisms of corneal graft rejection: the sixth annual Thygeson Lecture, presented at the Ocular Microbiology and Immunology meeting, October 21, 2000. Cornea. 2001;20:675-679.
18. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci. 1991;32:2723-2728.
19. Ayliffe W, Alam Y, Bell EB, et al. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol. 1992;76:602-606.
20. Roelen DL, van Beelen E, van Bree SP, et al. The presence of activated donor HLA class I-reactive T lymphocytes is associated with rejection of corneal grafts. Transplantation. 1995;59:1039-1042.
21. Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 2001; 42:386-392.
22. Hegde S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci. 2000;41:3341-3347.
23. Group TCCTSR. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992;110:1392-1403.
24. Borderie VM, Lopez M, Vedie F, et al. ABO antigen blood-group compatibility in corneal transplantation. Cornea. 1997;16:1-6.
25. Dana MR, Yamada J, Streilein J W. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation. 1997;63:1501-1507.
26. Khoudadoust AA, Karnema Y. Corneal grafts in the second eye. Cornea. 1984;3:17-20.
27. Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. Surv Ophthalmol. 2007; 52:375-396.
28. Tugal-Tutkun I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology. 1995;102:576-585.
29. Yeh SP, Pflugfelder SC, Stern ME. Pathological effects of lacrimal keratoconjunctivitis on the ocular surface. In: Pflugfelder SC, Beuerman RW, Stern ME, eds. Dry Eye and Ocular Surface Disorders. New York: Marcel Dekker; 2004.
30. Choudhury A, Pakalnis VA, Bowers WE. Function and cell surface phenotype of dendritic cells from rat cornea. Invest Ophthalmol. 1995;36:2602-2613.
31. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies. Ophthalmology. 1994;10:1536-1547.
32. Naacke HG, Borderie, VM, Bourcier T, et al. Outcome of Corneal transplantation rejection. Cornea. 2001;20:350-353.
33. Khoudadoust AA, Abizadeh AA. The fate of corneal regrafts after previous rejection reactions. In: Silverstein AM, O'Connor GR, eds. Immunonology and Immunopathology of the Eye. New York: Masson Publishing; 1979:167-173.
34. Donshik PC, Cavanagh HD, Boruchoff SA, et al. Effect of bilateral and unilateral grafts on the incidence of rejections in keratoconus. Am J Ophthalmol. 1979;87:823-826.
35. Maumenee A. Corneal Graft Failure. CIBA Foundation Symposium. Amsterdam: Elsevier; 1973:208.
36. Arentsen J. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361-402.
37. Stulting RD, Sumers KD, Cavanagh HD, et al. Penetrating keratoplasty in children. Ophthalmology. 1984;91:1222-1230.
38. Sellami D, Abid S, Bouaouaja G, et al. Epidemiology and risk factors for corneal graft rejection. Transplant Proc. 2007;39:2609-2611.
39. Epstein AJ, de Castro TN, Laibson PR, et al. Risk factors for the first episode of corneal graft rejection in keratoconus. Cornea. 2006;25:1005-1011.
40. Inoue K, Tsuru T. ABO antigen blood-group compatibility and allograft rejection in corneal transplantation. Acta Ophthalmol Scand. 1999;77:495-499.
41. Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. Am J Ophthalmol. 2002;133:437-443.
42. Vail A, Gore SM, Bradley BA, et al. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation. 1994;58:1210-1216.
43. Mannis MJ, Holland EJ, Beck RW, et al; Cornea Donor Study Group. Clinical profile and early surgical complications in the Cornea Donor Study. Cornea. 2006;26:164-170.
44. Redbrake C, Sieben P, Salla S, et al. Effect of donor illness on endothelial cell number of human corneas. Klin Monatsbl Augenheilkd. 1995;206:46-48.
45. Khoudadoust AA, Silverstein AM. Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol. 1969;8:180-195.
46. Mabon M, Boisjoly H. Penetrating keratoplasty. In: Foster CS Azar DT, Dohlman CH, eds. The Cornea Scientific Foundations and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2005:1022-1041.
47. Shapiro MB, Mannis MJ, Krachmer JH. Rejection. In: Bright B, ed. Corneal Surgery, Theory, Technique and Tissues. Vol 2. St Louis: Mosby Company; 1997:254-268.
48. Stulting RD, Waring GO, Bridges WZ, et al. Effect of donor epithelium on corneal transplant survival. Ophthalmology. 1988;95:803-812.
49. Krachmer JH, Alldredge OC. Subepithelial infiltrates: a probable sign of corneal graft rejection. Arch Ophthalmol. 1978;96:2234-2237.
50. Polack FM, Williams AK. Electron microscopic studies of graft endothelium in corneal graft rejection. Am J Ophthalmol. 1972;73:711-717.
51. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Ophthalmology. 1990;98:329-333.
52. Hill J. Immunosuppression in corneal transplantation. Eye. 1995;9:247-253.
53. Coster DJ, Kanai A. Management of high-risk corneal grafts. Eye. 2003; 17: 996-1002.
54. Reinhard T, Sundmacher R, Godehardt E, et al. Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. Ophthalmology. 1997;94:496-500.
55. Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307-318.
56. Hill J. Systemic cyclosporin in high-risk keratoplasty. Ophthalmology. 1994;101:128-133.
57. Price MO, Price FW, Jr. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785-1790.
58. Ippoliti G, Fronterre A. Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc. 1987;19:2579-2580.
59. Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology. 2007;114:1950.
60. Pleyer U, Bertelmann E, Rieck P, et al. Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefe Arch Clin Exp Ophthalmol. 2000;238:531-536.
61. Qian Y, Dekaris I, Yamagami S. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol. 2000;118:1666-1671.
62. Yamada J, Zhu SN, Streilein JW. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000;41:4203-4208.